Global Viral Hepatitis Market – Industry Trends and Forecast to 2029

Market Analysis and Size

According to WHO data published in July 2021, 296 million individuals worldwide were living with chronic hepatitis B virus by 2019, with 1.5 million new infections each year. The highest rates of Hepatitis B infection are found in the WHO regions of the West Pacific and Africa, where 6.2 percent and 6.1 percent of people, respectively, are affected. Inflammation of the liver is referred to as hepatitis. Inflammation is the body's reaction to irritation or injury, and it usually causes swelling and pain

Data Bridge Market Research analyses that the viral hepatitis market was valued at USD 14.98 billion in 2021 and is expected to reach USD 19.73 billion by 2029, registering a CAGR of 3.50% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Viral hepatitis is a long-term or severe infection that causes liver enlargement and inflammation. Contaminated food and water are the sources of the disease. It is contagious and spreads by close contact with bodily fluids such sweat, stool and blood. Antiviral drugs are a type of medicine that is used to treat viral illnesses like HIV, herpes, hepatitis, and influenza. Vaccines are the most common form of administration for these medications. Furthermore, the majority of these medications are used to treat specific viral infections, but a select handful (broad-spectrum antiviral treatments) are effective against different virus forms. Antiviral medications used to treat viral infections of the liver, such as hepatitis, are known as hepatic antiviral agents.

Viral Hepatitis Market Dynamics

Drivers

• Rise in the prevalence of hepatitis

The rising prevalence of hepatitis is a major factor driving the viral hepatitis market's growth rate. According to World Health Organization (WHO) data published in July 2021, an estimated 58 million individuals have chronic hepatitis C virus infection, with 1.5 million new infections occurring each year. The hepatitis C virus is a blood-borne pathogen, and the most common way to contract it is by contact with small amounts of blood. This frequently occurs as a result of improper injections and poor health care. 

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of viral hepatitis market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness about the will expand the viral hepatitis market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of viral hepatitis market. Along with this, rising geriatric population and surge in medical tourism will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the viral hepatitis market growth. In March 2021, Dicerna Pharmaceuticals and Roche began a Phase II combo trial for the treatment of chronic hepatitis B virus (HBV) infection with the experimental GalXC RNAi candidate, RG6346. As a result, market research and development activities are crucial to improve market expansion.

• Launch of new products

The launch of new products is estimated to boost the new market opportunities. Mavyret (glecaprevir and pibrentasvir) pills, for instance, were approved by the US Food and Drug Administration in April 2019 to treat six genotypes of hepatitis C virus (HCV) in children aged 12 to 17. Furthermore, in June 2021, Gilead Sciences, Inc. got FDA approval for Epclusa for the treatment of chronic hepatitis C virus (HCV) in children under the age of three, regardless of HCV genotype or severity of liver disease.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the viral hepatitis market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost of the treatment will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and low awareness about viral hepatitis will pose major challenges to the market's growth rate. Additionally, the dearth of skilled professionals and strict government regulations will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This viral hepatitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the viral hepatitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Viral hepatitis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Viral Hepatitis Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery, while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, and inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of viral hepatitis in recent months.

Recent Development

• In May 2022, Abbott announced the launch of HBsAg Next Assay in India for early detection of Hepatitis B. The HBsAg Next Qualitative Assay identifies HBV surface antigen (HBsAg) in human serum and plasma, making it a sophisticated, next-generation assay for earlier detection of HBV. It also overcomes typical obstacles by demonstrating the greatest level of assay performance needed to detect infection in immunocompromised individuals.

Global Viral Hepatitis Market Scope

The viral hepatitis market is segmented on the basis of disease type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Hepatitis A
• Hepatitis B
• Hepatitis C
• Others

Treatment

• Antiviral Drugs
• Telbivudine
• Entecavir
• Tenofovir disoproxil
• Lamivudine
• Others
• Vaccine
• Immune Modulator Drugs
• Pegylated interferon
• Interferon alpha
• Surgery
• Others

Diagnosis

• Liver Biopsy
• Blood Tests
• Imaging Tests
• Ultrasound
• MRI
• CT scan
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Viral Hepatitis Market Regional Analysis/Insights

The viral hepatitis market is analysed and market size insights and trends are provided by country, disease type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the viral hepatitis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the viral hepatitis market because of the growing presence of major key players and rising number of research and development activities will further propel the market's growth rate in this region. Additionally, an increase in the number of FDA approval drugs will further propel themarket's growth rate in this region. 

Asia-Pacific are expected to grow during the forecast period due to surging number of generic manufacturers and growing government initiatives in this region. Also, the development of healthcare infrastructure will further propel themarket's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Viral Hepatitis Market Share Analysis

The viral hepatitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to viral hepatitis market.

Some of the major players operating in the viral hepatitis market are:

• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Boehringer Ingelheim International GmbH. (Germany)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Cadila Pharmaceuticals (India) 
• Eli Lilly and Company (U.S.)
• LEO Pharma A/S (Denmark)
• Cipla Inc. (U.S.)
• Aurobindo Pharma (India)
• Lupin (India)
• Sumitomo Corporation (Japan)

SKU-53352